References
1. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. Peritoneal dialysis related infections recommendations: 2010 update. Perit dial int 2010;30:393–423.
2. Kim DK, Yoo TH, Ryu DR, Xu ZG, Kim HJ, Choi KH, et al. Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. Perit dial int 2004;24:424–32.
3. Nathisuwan S, Burgess DS, Lewis JS 2nd. Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001;21:920–8.
4. Palucha A, Mikiewicz B, Gniadkowski M. Diversification of escherichia coli expressing an SHV-type extended-spectrum beta-lactamase (ESBL) during a hospital outbreak: Emergence of an ESBL-hyperproducing strain resistant to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1999;43:393–6.
5. Yip T, Tse KC, Lam MF, Tang S, Li FK, Choy BY, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients. Perit dial int 2006;26:191–7.
6. Tedla FM, Salifu M, Friedman EA. Successful treatment of vancomycin-resistant enterococcal peritonitis with linezolid in a kidney transplant patient: a case report and review of the literature. Perit Dial Int 2004;24:70–2.
7. Valdes-Sotomayor J, Cirugeda A, Bajo MA, del Peso G, Escudero E, Sanchez-Tomero JA, et al. Increased severity of escherichia coli peritonitis in peritoneal dialysis patients independent of changes in in vitro antimicrobial susceptibility testing. Perit Dial Int 2003;23:450–5.
8. Troidle L, Gorban-Brennan N, Kliger A, Finkelstein F. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998;32:623–8.
9. Saklayen MG. CAPD peritonitis. Incidence, pathogeng, diagnosis, and management. Med Clin North Am 1990;74:997–1010.
10. Park SH, Lee DH, Cho YJ, Cho DK, Shin SK, Kim DJ, et al. Causative organisms and patterns of antibiotics sensitivity of capd peritonitis in different dialysis centers. Korean J Med 2003;64:682–9.
11. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163–7.
12. Khurana S, Taneja N, Sharma M. Extended spectrum beta-lactamase mediated resistance in urinary tract isolates of family enterobacteriaceae. Indian J Med Res 2002;116:145–9.